<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764748</url>
  </required_header>
  <id_info>
    <org_study_id>SMT-YJ-201701</org_study_id>
    <nct_id>NCT03764748</nct_id>
  </id_info>
  <brief_title>Selective Microbiota Transplantation for Tourette's Syndrome</brief_title>
  <acronym>mini-FMT</acronym>
  <official_title>Efficacy and Safety of Selective Microbiota Transplantation for Tourette's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faming Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the role of selective microbiota transplantation on Tourette's
      syndrome (TS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging scientific data support the significant role of microbiota in the modulation of the
      central nervous system. The reconstitution of gut microbiota might be a potential option to
      treat Tourette's syndrome (TS). This study aims to evaluate the role of selective microbiota
      transplantation on Tourette's syndrome (TS). Patients aged 7 to 60 years old with TS and a
      Yale Global Tic Severity Scale (YGTSS) -total tic score â‰¥20 will be enrolled in this
      open-label clinical trial. Participants will receive 200ml selective microbiota suspension
      (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal
      transendoscopic enteral tubing (TET) tube for 3 days. Clinical evaluations before, 1, 4 and 8
      weeks after mini-FMT will be assessed with the YGTSS, the Gilles de la Tourette Syndrome
      Quality-of-Life Scale (GTS-QOL), the Clinical Global Impression (CGI)-Severity, the
      Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Beck Depression Inventory (BDI) and the
      Beck Anxiety Inventory (BAI). 16S rRNA stool analysis will be performed to assess associated
      microbial changes. The urinary metabolic profiles of those patients will be generated using
      nuclear magnetic resonance (NMR) spectroscopy. Safety will be assessed in all patients after
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of Yale Global Tic Severity Scale total score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of tic severity according to the Yale Global Tic Severity Scale total score at 8 weeks after treatment. Yale Global Tic Severity Scale total score ranges 0-100, and higher values represent a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Clinical Global Impressions-Improvement scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Positive treatment response was defined by a score of 1 (very much improved) or 2 (much improved) on the Clinical Global Impressions-Improvement scale. The Clinical Global Impression - Improvement scale is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as:1.Very much improved; 2.Much improved; 3. Minimally improved; 4. No change; 5. Minimally worse; 6. Much worse; 7.Very much worse. The Clinical Global Impressions-Improvement scale score will recorded at week 8 after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Clinical Global Impression-Severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Clinical Global Impression-Severity scale is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 1.Normal, not at all; 2.Borderline mentally; 3. Mildly; 4.Moderately; 5. Markedly; 6. Severely; 7. Among the most extremely. The change of Clinical Global Impression-Severity will be recorded at week 8 after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Gilles de la Tourette Syndrome Quality-of-Life Scale score</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Gilles de la Tourette Syndrome Quality-of-Life Scale addresses the issue of how the illness affects patients' well-being. It ranges from 0 to108, and higher values represent a worse outcome. The change of life quality according to the Gilles de la Tourette Syndrome Quality-of-Life Scale score at 1 week, 2 weeks and 8 weeks after treatment.The change of Gilles de la Tourette Syndrome Quality-of-Life Scale score will be recorded at week 8 after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tourette Syndrome</condition>
  <arm_group>
    <arm_group_label>mini-FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mini-FMT</intervention_name>
    <description>200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) will be delivered daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.</description>
    <arm_group_label>mini-FMT</arm_group_label>
    <other_name>Selective microbiota transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  7-60 years old with Tourette or chronic tic disorder of moderate or greater severity
             as measured by a Yale Global Tic Severity Scale-Total score&gt;25

        Exclusion Criteria:

          -  Complicated with certain brain disease, including tumor,injury,cerebrovascular
             disease;

          -  Complicated with other severe disease, including cancers, organ failure, heart
             diseases;

          -  Follow-up less than 8 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faming Zhang, MD; PHD</last_name>
    <role>Study Chair</role>
    <affiliation>The Second Hospital of Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faming Zhang, MD; PHD</last_name>
    <phone>025-58509883</phone>
    <email>fzhang@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Ding, MD</last_name>
    <phone>86-15250963899</phone>
    <email>xding@njmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fmt-Dt-N-27/1350</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, PhD,MD</last_name>
      <phone>86-025-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Faming Zhang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, MD, PhD</last_name>
      <phone>086-25-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hoffman BU, Lumpkin EA. A gut feeling. Science. 2018 Sep 21;361(6408):1203-1204. doi: 10.1126/science.aau9973.</citation>
    <PMID>30237346</PMID>
  </reference>
  <reference>
    <citation>Foster JA. Targeting the Microbiome for Mental Health: Hype or Hope? Biol Psychiatry. 2017 Oct 1;82(7):456-457. doi: 10.1016/j.biopsych.2017.08.002.</citation>
    <PMID>28870296</PMID>
  </reference>
  <reference>
    <citation>Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011 Apr;20(4):173-96. doi: 10.1007/s00787-011-0163-7. Erratum in: Eur Child Adolesc Psychiatry. 2011 Jul;20(7):377.</citation>
    <PMID>21445724</PMID>
  </reference>
  <reference>
    <citation>Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. Endosc Int Open. 2016 Jun;4(6):E610-3. doi: 10.1055/s-0042-105205. Epub 2016 Apr 28.</citation>
    <PMID>27556065</PMID>
  </reference>
  <reference>
    <citation>Zhang F, Cui B, He X, Nie Y, Wu K, Fan D; FMT-standardization Study Group. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018 May;9(5):462-473. doi: 10.1007/s13238-018-0541-8. Epub 2018 Apr 24. Review.</citation>
    <PMID>29691757</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>September 21, 2019</last_update_submitted>
  <last_update_submitted_qc>September 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Faming Zhang</investigator_full_name>
    <investigator_title>Associate professor, Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Tic Disorders</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Brain-gut axis</keyword>
  <keyword>Microbiota Transplantation</keyword>
  <keyword>Tourette syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

